Novo Nordisk Pharma AG
http://www.novonordisk.ch
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Novo Nordisk Pharma AG
Why US Payers Aren’t Reimbursing Obesity Meds
Payers are restricting access to obesity drugs due to huge patient numbers and a wave of innovation in other areas
EU: ‘Urgent Action’ Needed From Industry & Member States To Curb GLP-1 Shortages
The off-label “cosmetic” use of GLP-1 receptor agonists such as Ozempic and Wegovy is contributing to global shortages of these drugs, prompting the European Medicines Agency to ask member states and manufacturers to “control and optimize” their use.
US House Bill Would Cover Obesity Drugs For Only Sliver Of New Medicare Enrollees
The significantly scaled back version of the Treat and Reduce Obesity Act is expected to cost the Part D program $1.7bn over 10 years.
AstraZeneca Targets $80bn Sales By 2030 But Analysts Still To Be Convinced
The UK company has unveiled a new strategy for 2030 and beyond but analysts' forecasts fall around $15bn short of the company’s own projections.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice